Cerus (NASDAQ:CERS) Downgraded by Wall Street Zen to Hold

Wall Street Zen lowered shares of Cerus (NASDAQ:CERS) from a buy rating to a hold rating in a research report sent to investors on Saturday morning.

Separately, TD Cowen restated a “buy” rating on shares of Cerus in a research report on Monday, January 12th. One investment analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Hold”.

Cerus Stock Down 5.4%

CERS opened at $1.93 on Friday. Cerus has a twelve month low of $1.12 and a twelve month high of $2.95. The company has a quick ratio of 1.29, a current ratio of 1.73 and a debt-to-equity ratio of 0.62. The company has a 50-day moving average price of $2.31 and a 200 day moving average price of $1.85. The company has a market cap of $370.89 million, a PE ratio of -24.13 and a beta of 1.51.

Cerus (NASDAQ:CERS) last posted its quarterly earnings data on Monday, March 2nd. The biotechnology company reported ($0.01) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.01). Cerus had a negative return on equity of 26.09% and a negative net margin of 7.58%.The company had revenue of $64.58 million for the quarter, compared to analysts’ expectations of $59.31 million. Sell-side analysts expect that Cerus will post -0.08 earnings per share for the current fiscal year.

Institutional Trading of Cerus

Large investors have recently bought and sold shares of the business. Assenagon Asset Management S.A. lifted its position in Cerus by 29.3% during the third quarter. Assenagon Asset Management S.A. now owns 1,583,702 shares of the biotechnology company’s stock worth $2,518,000 after buying an additional 358,548 shares in the last quarter. Acadian Asset Management LLC grew its holdings in Cerus by 38.6% in the 2nd quarter. Acadian Asset Management LLC now owns 2,632,304 shares of the biotechnology company’s stock valued at $3,710,000 after buying an additional 733,683 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. increased its stake in shares of Cerus by 49.2% in the 2nd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 296,099 shares of the biotechnology company’s stock worth $418,000 after acquiring an additional 97,592 shares during the last quarter. Savant Capital LLC increased its stake in shares of Cerus by 339.6% in the 2nd quarter. Savant Capital LLC now owns 94,812 shares of the biotechnology company’s stock worth $134,000 after acquiring an additional 73,244 shares during the last quarter. Finally, Los Angeles Capital Management LLC raised its holdings in shares of Cerus by 30.5% during the 2nd quarter. Los Angeles Capital Management LLC now owns 367,389 shares of the biotechnology company’s stock worth $518,000 after acquiring an additional 85,835 shares during the period. Hedge funds and other institutional investors own 78.37% of the company’s stock.

Cerus Company Profile

Cerus Corporation is a biomedical products company dedicated to enhancing the safety of blood transfusions worldwide. Its flagship offering, the INTERCEPT Blood System, employs pathogen reduction technology designed to inactivate a broad spectrum of viruses, bacteria, and parasites in donated platelets and plasma. This approach aims to mitigate the risk of transfusion-transmitted infections and improve blood component safety for patients.

The INTERCEPT platform integrates seamlessly into existing blood center workflows, providing a one-step treatment process for collected blood products.